StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Aegis Capital Affirms Acadia Pharma (ACAD) at 'Buy' Following Positive FDA Panel Review; Sees Nuplazid Approval Soon
March 30, 2016 10:44 AM
Aegis Capital affirms Acadia Pharma (Nasdaq: ACAD) with a Buy rating and $54 price target following a positive FDA panel ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Acadia Pharma (ACAD) Fades Early Gains
March 30, 2016 11:56 AM
Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid
March 30, 2016 6:49 AM
Acadia Pharmaceuticals (ACAD) PT LIfted to $44 at Piper Jaffray Amid Panel Backing for NUPLAZID
March 30, 2016 6:26 AM
Acadia Pharma (ACAD) Surges 25% as Trading Resumes
March 29, 2016 5:52 PM
Acadia Pharma (ACAD) Resumes Trading at 5:45 PM ET
March 29, 2016 5:43 PM
Acadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's Disease
March 29, 2016 5:14 PM
FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
March 29, 2016 5:13 PM
